Contact HealthDay
Tel: 203.855.1400 or E-mail

News By Specialty

Allergy
Anesthesiology
Cardiology
Cosmetic Surgery
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Practice
Gastroenterology
Geriatrics
Hematology & Oncology
HIV & AIDS
Infectious Disease
Internal Medicine
Nephrology
Neurology
Nursing
OBGYN & Women's Health
Ophthalmology
Orthopedics
Otolaryngology
Pain Management
Pathology
Pediatrics
Pharmacy
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Follow us on:

    


e-Healthcare Leadership Awards


Intestinal Barrier Sleeve Shows Benefit in Rat Model of Diabetes
Reduction in body weight from loss of fat mass; improvements in glucose, lipid homeostasis

MONDAY, Oct. 21 (HealthDay News) -- Implantation of a duodenal-endoluminal sleeve (DES) correlates with reductions in body weight (BW) from loss of fat mass, and with improvements in glucose and lipid homeostasis in a rat model of diabetes, according to an experimental study published online Oct. 9 in Gut.

Kirk M. Habegger, Ph.D., from the University of Cincinnati, and colleagues randomized Zucker Diabetic Fatty rats to naive, sham ad libitum, sham pair-fed, and DES implanted groups. For 28 days postoperatively, food intake, BW, and body composition were measured. In addition, glucose, lipid, and bile acid metabolism were evaluated and histological assessment of the upper intestine was made.

The researchers found that DES implantation led to a sustained reduction in BW throughout the study, which was matched by pair-fed sham animals. Loss of fat, but not lean mass, led to decreased BW. Compared with ad libitum-fed or pair-fed sham controls, DES rats were found to be more glucose tolerant. Circulating triglyceride and glycerol levels were also reduced with DES, while circulating bile acids increased. DES triggered increases in villus length throughout the upper intestine.

"Our preclinical results validate DES as a promising therapeutic approach to diabetes and obesity, which offers reversibility, low risk, low invasiveness and triple benefits including fat mass loss, glucose and lipid metabolism improvement which mechanistically may involve increased villus growth in the upper gut," the authors conclude.

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)



Copyright © 2013 HealthDay. All rights reserved.

July 23, 2014

Archive Search

By Keyword:
By Category:
By Topic:

Related Articles

Decreased Vision Tied to Unemployment

Online Reviews Show Patients Value Docs' Interpersonal Skills

Weight Loss Over Two Years Predicts Reduced Diabetes Risk CME

Physician Offices Investing in Patient Portals for EHRs

National Survey Finds Most U.S. Physicians Are Satisfied

Good Response for Sofosbuvir + Ribavirin in HIV/HCV Coinfection